N Kro¨ger et al. recently reported the results of a retrospective analysis of 65 patients undergoing autologous stem cell transplantation for therapy-related acute myeloid leukemia (t-AML) and myelodysplastic syndrome (t-MDS). The authors analyzed European bone marrow transplantation registry data and showed that the KaplanMeier estimates of the probability of 3-year overall and disease-free survival were 35 and 32%, respectively.
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1 These figures exceed the results obtained with allogeneic stem cell transplantation and support the autologous approach as an alternative for patients with t-AML/t-MDS. 2, 3 The data presented in this publication, however, should be interpreted with caution. t-AML and t-MDS differ markedly from their de novo counterparts. Clonal chromosomal aberrations are detected in up to 97% of cases with t-AML/t-MDS and cytogenetic markers indicating a poor prognosis (7q-/-7, 5q-/-5, rearrangements involving 11q23 and complex aberrant karyotypes) predominate. [4] [5] [6] In contrast, the patient collective described by Kro¨ger et al. showed a normal karyotype in 14/34 (41%) cases with available cytogenetics and high-risk markers in only 7/34 (23%). Furthermore, 33/65 (51%) patients were younger than 40 years, indicating a lower median age than that reported in large t-AML/t-MDS studies which was uniformly over 50 years. 4, 6, 7 Taken together, the favorable results obtained with autologous transplantation in patients with t-AML/t-MDS may be -at least in part -attributable to a patient population with favorable clinical and biologic characteristics. Until there are prospective studies evaluating autologous transplantation, allogeneic transplantation should remain the preferred transplantation approach in patients with t-AML/t-MDS. 
